(UroToday.com) The Advanced Prostate Cancer Consensus Conference 2021 virtual meeting session discussing PSMA in diagnostics and therapy included a presentation by Dr. Piet Ost questioning PSMA PET as the best modality for staging to improve clinical outcomes of prostate cancer patients.
(UroToday.com) The first session of the Advanced Prostate Cancer Consensus Conference 2021 which was hosted in the context of the COVID-19 pandemic focused on the management of patients with newly diagnosed metastatic hormone-sensitive prostate cancer. While a number of presenters discussed the evidence for treatment intensification (including up to “triplet therapy”), Dr. Robert Jones discussed whether […]
(UroToday.com) The third and final session of the Advanced Prostate Cancer Consensus Conference 2021 which was hosted virtually in the context of the COVID-19 pandemic focused on molecular characterization of both tissue and blood, with a focus on implications for treatment with PARP inhibitors and beyond. Following the conference presentations, Dr. Matthew Smith and Dr. Nicholas […]
(UroToday.com) The second session of the Advanced Prostate Cancer Consensus Conference 2021 which was hosted in the context of the COVID-19 pandemic focused on the role of prostate-specific membrane antigen (PSMA) imaging in prostate cancer diagnostics and therapy. Dr. Michael Hofman discussed the role of concomitant FDG-based PET with PSMA-PET for patient selection.
(UroToday.com) The Advanced Prostate Cancer Consensus Conference 2021 meeting session discussing the management of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) included a discussion of the nine key panel questions specific to the mHSPC disease space. Dr. Bertrand Tombal and Dr. Nicholas James started with the results of question #12: In the majority of patients with […]
(UroToday.com) The second session of the Advanced Prostate Cancer Consensus Conference 2021 which was hosted in the context of the COVID-19 pandemic focused on the role of prostate specific membrane antigen (PSMA) imaging in prostate cancer diagnostics and therapy. Following the conference presentations, Dr. Neal Shore and Dr. Alberto Bossi led a discussion of the consensus […]
(UroToday.com) In this session, Dr. Ian Davis reviewed the evidence for “triplet therapy” comprising ADT plus docetaxel plus additional systemic therapy in metastatic hormone sensitive prostate cancer (mHSPC). He began with a high-level summary of five clinical trials that included patients treated with triplet therapy: TITAN, ARCHES, ENZAMET, PEACE-1, AND STAMPEDE M0. He noted key […]
(UroToday.com) The Advanced Prostate Cancer Consensus Conference 2021 meeting session discussing management of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) included a presentation by Dr. Karim Fizazi regarding the evidence for “triplet therapy”, specifically ADT + radiation + primary additional systemic therapy.
(UroToday.com) In this session, Dr. Karim Fizazi reviewed evidence for “triplet therapy” comprising ADT plus radiation (RT) to the primary plus additional systemic therapy in metastatic hormone sensitive prostate cancer (mHSPC). He began by reviewing the evidence for each of these therapies individually in mHSPC, noting that systemic therapy should be intensified for most men with […]
(UroToday.com) The first session of the Advanced Prostate Cancer Consensus Conference (APCCC) 2021 which was hosted virtually in the context of the COVID-19 pandemic focused on the management of patients with newly diagnosed metastatic hormone-sensitive prostate cancer. Previous presentations in this session have discussed a variety of treatment options for patients in this disease space: […]
